CA2516863A1 - Poloxamer emulsion preparations - Google Patents

Poloxamer emulsion preparations Download PDF

Info

Publication number
CA2516863A1
CA2516863A1 CA002516863A CA2516863A CA2516863A1 CA 2516863 A1 CA2516863 A1 CA 2516863A1 CA 002516863 A CA002516863 A CA 002516863A CA 2516863 A CA2516863 A CA 2516863A CA 2516863 A1 CA2516863 A1 CA 2516863A1
Authority
CA
Canada
Prior art keywords
composition
copolymer
oil
emulsion
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002516863A
Other languages
French (fr)
Other versions
CA2516863C (en
Inventor
Steen Boye Jorsal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novasel Australia Pty Ltd
Original Assignee
Novasel Australia Pty Ltd
Steen Boye Jorsal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novasel Australia Pty Ltd, Steen Boye Jorsal filed Critical Novasel Australia Pty Ltd
Publication of CA2516863A1 publication Critical patent/CA2516863A1/en
Application granted granted Critical
Publication of CA2516863C publication Critical patent/CA2516863C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90—Block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

An emulsion composition comprising: an aqueous component, a non-ionic block copolymer, and an oil wherein the copolymer comprises at least 10% by weight of the composition.

Claims (61)

1. An emulsion composition comprising: an aqueous component, a non-ionic block copolymer, and an oil wherein the copolymer comprises at least 10% by weight of the composition, and wherein the composition is thermoreversible.
2. An emulsion composition comprising: an aqueous component, a non-ionic block copolymer, a hydrophilic, non-ionic short chain fatty acid emulsifier, and an oil wherein the copolymer comprises at least 10% by weight of the composition, and wherein the composition is thermoreversible.
3. A method for preparing an emulsion composition, comprising the steps of:
(a) Mixing a copolymer with an aqueous solution at a suitable temperature to substantially dissolve the copolymer in the aqueous solution; and (b) Mixing, at cold temperature, an oil that is the active agent or has a water-insoluble active agent dissolved therein, with the aqueous copolymer solution prepared in step (a) to form an emulsion;
wherein said composition comprises at least 10% by weight of copolymer.
4. The method of claim 3 wherein the oil is mixed with the aqueous copolymer solution prepared in step (a) at a temperature less than about 15°C.
5. The method of claim 3 wherein the oil is mixed with the aqueous copolymer solution prepared in step (a) at a temperature between about 4°C to 12°C
6. The method of claim 3 wherein the oil is mixed with the aqueous copolymer solution prepared in step (a) at a temperature less than about 10°C.
7. A method for preparing an emulsion composition, comprising the steps of:

(a) Mixing a copolymer with an aqueous solution at a suitable temperature to substantially dissolve the copolymer in the aqueous solution;
(b) Mixing a hydrophilic, non-ionic short chain fatty acid emulsifier with an oil that is the active agent or has a water-insoluble active agent dissolved therein, at a low temperature to form an oil mixture; and (c) Mixing the solution prepared in step (a) with the solution prepared in step (b) at a low temperature to form an emulsion;
wherein said composition comprises at least 10% by weight of copolymer.
8. The method of claim 7 wherein the solution prepared in step (a) is mixed with the solution prepared in step (b) at a temperature less than about 60°C.
9. The method of claim 7 wherein the solution prepared in step (a) is mixed with the solution prepared in step (b) at a temperature between about 15°C to 40°C
10. The method of claim 7 wherein the solution prepared in step (a) is mixed with the solution prepared in step (b) at a temperature between about 20°C to 30°C
11. The method of claim 7 wherein the solution prepared in step (a) is mixed with the solution prepared in step (b) at room temperature.
12. The method of claim 3 or 7 wherein the copolymer is dissolved at a temperature of about 6°C.
13. The method of claim 3 or 7 wherein the copolymer is dissolved at room temperature with semi-continuous or continuous stirring.
14. An emulsion composition formed by the method of claim 3.
15. An emulsion composition formed by the method of claim 7.
16. The composition of any one of claims 1, 2, 14 or 15 wherein the emulsion is a microemulsion.
17. The composition of any one of claims 1, 2, 14 or 15 wherein the copolymer comprises about 10% to 50% by weight of the composition.
18. The composition of any one of claims 1, 2, 14 or 15 wherein the copolymer comprises about 10.1 % to 40% by weight of the composition.
19. The composition of any one of claims 1, 2, 14 or 15 wherein the copolymer comprises an amount by weight of the block copolymer between any of the following ranges: 10.5% to 35%, 11% to 30%, 12% to 25%, 13% to 20% or 14% to 18% by weight of the composition.
20. The composition of any one of claims 1, 2, 14 or 15 wherein the copolymer comprises 15% by weight of the composition.
21. The composition of any one of claims 1, 2, 14 or 15 wherein the copolymer comprises a thermo-reversible copolymer.
22. The composition of claim 20 wherein the copolymer comprises a block copolymer of ethylene oxide and propylene oxide (poloxamer).
23. The composition of claim 22 wherein the copolymer is represented by the formula:
HO(C2H4O)a(C3H6O)b(C2H4O)a H
Where 'b' is between 15 and 67 and 'a' is between 2 and 130, and the total proportion of 'a' units amounts to from 20% to 90% by weight of the copolymer.
24. The composition of claim 23 wherein the molecular weight of the copolymer ranges from about 1,000 to 20,000.
25. The composition of claim 22 wherein the copolymer is poloxamer 407.
26. The composition of claim 2 or 15 wherein the emulsifier is a fatty acid component with a polyethoxylated side chain.
27. The composition of claim 2 or 15 wherein the emulsifier is chosen from the list comprising: Laureth-4, Laureth-9, Laureth-23, PPG-26-Buteth-26/PEG-40 Hydrogenated castor oil, and PEG-40 Hydrogenated castor oil.
28. The composition of claim 2 or 15 wherein the emulsifier comprises about 0.5% to 50% by weight of the microemulsion.
29. The composition of any one of claims 1, 2, 14 or 15 wherein the oil is an active agent or has a water-insoluble active agent dissolved therein.
30. The composition of any one of claims 1, 2, 14 or 15 wherein the oil is chosen from the list comprising: long chain alcohols, glyceryl esters of fatty acids or fatty esters of monohydric alcohols.
31. The composition of claim 30 wherein the esters and alcohols are liquids at room temperature.
32. The composition of any one of claims 1, 2, 14 or 15 wherein the oil contains active agents that are soluble in or miscible with the oil phase.
33. The composition of any one of claims 1, 2, 14 or 15 wherein the oil constitutes the active agent of the emulsion.
34. The composition of claim 33 wherein the oil contains active agents that are soluble in or miscible with the oil phase.
35. The composition of any one of claims 32 to 34 wherein the active agents are drawn from the group comprising: antimicrobials (such as antibiotics, antifungals and antivirals), anti-inflammatories, antihistaminics, antidepressants, anaesthetics antineoplastics, enzymes, cardiovascular agents, polynucleotides, genetic material, viral vectors, immunoactive agents, imaging agents, immunosuppressive agents, peptides, proteins and combinations thereof.
36. The composition of any one of claims 32 to 34 wherein the active agent is present in a pharmaceutically effective amount.
37. The composition of any one of claims 1, 2, 14 or 15 wherein the oil comprises about 0.1% to 80% by weight of the emulsion.
38. The composition of any one of claims 1, 2, 14 or 15 wherein the oil comprises about 1% to 30% by weight of the emulsion.
39. The composition of any one of claims 1, 2, 14 or 15 wherein the oil comprises about 3% to 15% by weight of the emulsion.
40. The composition of any one of claims 1, 2, 14 or 15 wherein the oil comprises 6% by weight of the emulsion.
41. The composition of any one of claims 1, 2, 14 or 15 wherein the oil is tea tree oil (TTO).
42. The composition of claim 41 that has microbicide activity.
43. The composition of any one of claims 1, 2, 14 or 15 wherein the emulsion possesses bioadhesive or mucoadhesive properties.
44. The composition of any one of claims 1, 2, 14 or 15 wherein the emulsion is in the form of a liquid or a gel.
45. The composition of claim 44 wherein the emulsion composition is a gel.
46. The composition of any one of claims 1, 2, 14 or 15 wherein the emulsion composition is a liquid that is capable of gelatinising upon contact with dermal or mucosal tissue.
47. Use of the composition of any one of claims 1, 2, 14 or 15 for topically application to the epidermal surfaces of an animal.
48. Use of the composition of any one of claims 1, 2, 14 or 15 for mucosal application to the oesophageal, otic, vaginal, rectal or ophthalmic surfaces of an animal.
49. Use according to claim 47 wherein the composition further comprises agents to promote bodily attractiveness or to mask the physical manifestations of a disorder or disease.
50. Use according to claim 49 wherein the composition also treats a physical disorder.
51. Use of the composition of any one of claims 1, 2, 14 or 15 to impart thickening properties to other compositions.
52. Use according to claim 51 wherein the composition imparts enhanced overall viscosity.
53. Use according to claim 51 wherein the composition imparts a viscosity response with temperature.
54. Use of the composition of any one of claims 1, 2, 14 or 15 to impart emolliency properties to other compositions.
55. Use of the composition of any one of claims 1, 2, 14 or 15 as a film-forming bioactive agent on the skin or other mucosal membrane.
56. A use according to claim 55 wherein the film-forming bioactive agent further acts as a barrier to prevent water loss from the skin.
57. Use of the composition of claim 42 to treat a disease selected from the group comprising: sexually transmitted diseases, HIV, impetigo, cold sores, otitis media, otitis externs, acne, periodontitis, gingivitis, paronychia, onychomycosis and secondary infections in connection with operations, dermatitis, burns, etc.
58. The composition of any one of claims 1, 2, 14 or 15 further comprising one or more pharmaceutically acceptable additives, excipients, carriers or diluents.
59. The composition of any one of claims 1, 2, 14 or 15 wherein the composition further comprises one or more pharmaceutically acceptable acids or a bases.
60. The composition of any one of claims 1, 2, 14 or 15 wherein the composition further comprises one or more pharmaceutically acceptable salts of an acid or a base.
61. The composition of any one of claims 1, 2, 14 or 15 wherein the composition further comprises one or more pharmaceutically acceptable enzyme inhibiting agents.
CA2516863A 2003-02-27 2004-02-20 Poloxamer emulsion preparations Expired - Fee Related CA2516863C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003900887A AU2003900887A0 (en) 2003-02-27 2003-02-27 Poloxamer emulsion preparations
AU2003900887 2003-02-27
PCT/AU2004/000218 WO2004076561A1 (en) 2003-02-27 2004-02-20 Poloxamer emulsion preparations

Publications (2)

Publication Number Publication Date
CA2516863A1 true CA2516863A1 (en) 2004-09-10
CA2516863C CA2516863C (en) 2011-12-06

Family

ID=31499933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2516863A Expired - Fee Related CA2516863C (en) 2003-02-27 2004-02-20 Poloxamer emulsion preparations

Country Status (9)

Country Link
EP (1) EP1597318A4 (en)
JP (1) JP2006519272A (en)
CN (1) CN100591721C (en)
AU (3) AU2003900887A0 (en)
BR (1) BRPI0408056A (en)
CA (1) CA2516863C (en)
EA (1) EA017434B1 (en)
NO (1) NO20054395L (en)
WO (1) WO2004076561A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190026056A (en) * 2008-04-21 2019-03-12 오토노미, 인코포레이티드 Auris formulations for treating otic diseases and conditions
WO2010076730A1 (en) * 2009-01-02 2010-07-08 Donald, Jenny Method for the treatment of an hiv infection
PL2552487T3 (en) * 2010-04-01 2017-04-28 Pharmanest Ab Thermogelling anaesthetic compositions
HUE042252T2 (en) * 2011-03-21 2019-06-28 Broda Tech Co Ltd Reversely thermo-reversible hydrogel compositions
ITMI20131927A1 (en) 2013-11-20 2015-05-21 Cosmo Technologies Ltd EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND / OR ENDOSCOPIC SUBMUCOSAL DISSECTION. EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTION AND / OR ENDOSCOPIC SUBMUCOSAL DISSECTION
KR102352250B1 (en) * 2014-03-25 2022-01-17 제넨테크, 인크. Methods of preparing a poloxamer for use in cell culture medium
US10266745B2 (en) 2017-02-03 2019-04-23 Saudi Arabian Oil Company Anti-bit balling drilling fluids, and methods of making and use thereof
KR101852718B1 (en) * 2017-04-04 2018-05-18 주식회사 제네웰 Kit for pain reduction of incision site after surgical operation
WO2019125783A1 (en) * 2017-12-21 2019-06-27 Sigma-Aldrich Co. Llc Poloxamer compositions and methods of making and using same
IT201900018752A1 (en) * 2019-10-14 2021-04-14 Alessandro Tosetti COMPOSITION BASED ON ESSENTIAL OILS FOR DENTAL USE FOR THE TREATMENT OF PERIODONTITIS AND PERIMPLANT MUCOSITE
RU2762506C1 (en) * 2021-01-20 2021-12-21 Общество С Ограниченной Ответственностью «Диамед-Фарма» Agent for applying oral and nasal cavities and method for its use as part of complex therapy of infectious and inflammatory diseases of nasal and oral cavities
CN114455621B (en) * 2022-01-11 2023-10-27 兰州交通大学 Preparation method of needle-shaped calcium carbonate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003429A1 (en) * 1988-09-23 1990-04-05 Cetus Corporation Lipid microemulsions for culture media
JPH0791555B2 (en) * 1989-12-22 1995-10-04 株式会社資生堂 Cleaning composition
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
ES2094688B1 (en) * 1994-08-08 1997-08-01 Cusi Lab MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION.
SE9601421D0 (en) * 1996-04-12 1996-04-12 Astra Ab New composition
DE19723308A1 (en) * 1997-06-04 1998-12-10 Wolfgang A Prof Dr Wohlrab Microemulsions useful for topical administration of e.g. local anaesthetics
FR2788007B1 (en) * 1999-01-05 2001-02-09 Oreal NANOEMULSION BASED ON BLOCK COPOLYMERS OF ETHYLENE OXIDE AND PROPYLENE OXIDE, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
AU2799099A (en) * 1999-03-01 2000-09-21 Basf Corporation Cold processed water-in-oil emulsions
CN1149984C (en) * 1999-06-21 2004-05-19 健一制药株式会社 Anesthetic compsn. for intravenous injection comprising propofol
SE0000774D0 (en) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs

Also Published As

Publication number Publication date
BRPI0408056A (en) 2006-02-14
WO2004076561A1 (en) 2004-09-10
CA2516863C (en) 2011-12-06
EP1597318A1 (en) 2005-11-23
CN100591721C (en) 2010-02-24
AU2009202265B2 (en) 2012-02-16
EA017434B1 (en) 2012-12-28
AU2003900887A0 (en) 2003-03-13
AU2009202265A1 (en) 2009-07-02
JP2006519272A (en) 2006-08-24
NO20054395L (en) 2005-09-22
AU2004215921A1 (en) 2004-09-10
EP1597318A4 (en) 2006-06-14
EA200501368A1 (en) 2006-02-24
CN1753949A (en) 2006-03-29

Similar Documents

Publication Publication Date Title
AU2009202265B2 (en) Poloxamer Emulsion Preparations
US8802116B2 (en) Poloxamer emulsion preparations
AU647922B2 (en) Improvements in or relating to organic compounds
US6774100B2 (en) Anhydrous creams, lotions and gels
US6005001A (en) Pharmaceutical composition
US4326977A (en) Liquid antiseptic cleaners with improved foaming properties
AU678039B2 (en) Stable topical retinoid compositions
US20130018104A1 (en) Emulsive composition containing dapsone
CA2524710A1 (en) Controlled release of active agents utilizing repeat sequence protein polymers
US20070122435A1 (en) Topical dapsone for the treatment of acne
US20090191138A1 (en) Novel topical formulations for improving the appearance of nails
CA1063515A (en) Tretinoin in a gel vehicle for acne treatment
US5728690A (en) Clear non-alcoholic hydrocortisone solutions
EP1320357B1 (en) Topical polymeric antimicrobial emulsion
US20070065385A1 (en) Cold production method for pearly lustre preparations containing alcohols
US20100004338A1 (en) Topical gel composition comprising azelaic acid
US20050255133A1 (en) Topical composition for acne treatment
KR950003611B1 (en) Antimycotic external lmidazole preparations
JP2000229810A (en) Composition for local use containing acetylenediol and use thereof for cleansing or removing makeup from skin, mucous membrane and hair
CA2535401C (en) Emulsive composition containing dapsone

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190220